Our findings warrant further studies to validate the combined effects of PAK1 and PAK4 on the tumour immune response of PDA in orthotopic mouse models where the biology of pancreatic cancer gets assessed anatomically, and in KPC mice with conditional knockout of PAK1 and/or PAK4 although it is challenging to generate these mice. The gene discussed is PAK1; the disease is Patent ductus arteriosus.